Insider trade

Director sold ~$13K of AMPH shares in the open market

Traded Nov 3, 2025 · Filed Nov 5, 2025

Why it stands out

A board member of Amphstar Pharmaceuticals sold $13K of Amphstar Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director<$25KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$12,633

Shares × reported transaction price

Timing vs results

88 days after results of Aug 7, 2025, 3 days before results of Nov 6, 2025

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+8.8%	+0.3%	+8.6%
30 days	+7.3%	+2.0%	+5.4%
90 days	+18.1%	+2.4%	+15.7%
180 days	−3.5%	+8.0%	−11.4%

Past results only. Not a forecast.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.